Iovance Biotherapeutics (IOVA) Tops Q2 EPS by 3c, misses on revenue

Iovance Biotherapeutics (NASDAQ: IOVA) reported Q2 EPS of ($0.47), $0.03 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $3.91 million.

For earnings history and earnings-related data on Iovance Biotherapeutics (IOVA) click here.

You May Also Be Interested In

• SanDisk and Micron surge as Apple confirms memory price pass-through
• Citi sees this stock as primary lithium demand beneficiary, upgrades to Buy
• Iovance Biotherapeutics (IOVA) files mixed shelf